RonanRx, Inc. dba RonanRx

FDA's Center for Drug Evaluation and Research (CDER), Office of Compounding Quality and Compliance, issued a warning letter dated October 30, 2026, to RonanRx, Inc. dba RonanRx, located at 1011 Old McDade Rd., Elgin, TX 78621 (FEI 3048890334), following a review of the firm's website and social media platforms conducted in September 2026. The review identified that RonanRx offers compounded semaglutide and tirzepatide products. FDA charged that the firm's website and its "X" (formerly Twitter) account (@Ronan_Rx) contain false or misleading representations causing those products to be misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §§ 352(a) and 352(bb), and that introduction of those misbranded products into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. § 331(a). FDA identified three categories of violations. First, compounded tirzepatide product images displayed on the website and posted on "X" carry a "RonanRx" label, falsely suggesting RonanRx is the compounder when FDA states it is not. Second, the website uses the phrases "Well-Studied Compounded Medications" and "FDA-Approved Compounded Medications," and the firm's "X" bio invites users to "Explore GLP-1s like Ozempic"; a pinned video states the products are "super [bleep] legit" at "seventy-eight dollars a month, for drugs like Ozempic." FDA concluded these claims represent that the compounded products have been FDA-approved or evaluated for safety and effectiveness, and that accompanying disclaimers noting approval status do not cure the misleading overall impression. Third, the pinned video describes the products as "American made" and "farm-to-table drugs" and closes with imagery of an American flag and confetti. FDA's records contain no drug listings for semaglutide or tirzepatide active pharmaceutical ingredients intended for compounding that identify a U.S.-registered establishment as the drug substance manufacturer. FDA found that characterizing the finished product as domestically produced, while reinforcing that claim with patriotic imagery, conceals the true foreign origin of the active pharmaceutical ingredient and creates the misleading impression of domestic origin indicative of superior quality. FDA directed RonanRx to respond in writing to OCQC within 15 working days of receipt, identifying the entities that produce the compounded products, providing representative labeling samples, and demonstrating that false or misleading website and social media claims have been removed or corrected. FDA warned that failure to adequately address the violations may result in legal action including seizure and injunction, and noted that receipt in interstate commerce of misbranded products also constitutes a violation under section 301(c) of the FD&C Act, 21 U.S.C. § 331(c).